FAQ/Help |
Calendar |
Search |
Today's Posts |
02-20-2015, 05:04 PM | #1 | ||
|
|||
Member
|
In their double-blind, randomized, placebo-controlled trial - the first in human patients - researchers at Lund University and Karolinska Institutet in Sweden tested the safety and tolerability of PDGF in 12 patients with Parkinson's disease.
The treatment - PDGF or placebo - was delivered via a pump surgically implanted in the abdomen, with an internal catheter that went up into the brain. The pump delivered the drug for 12 days, and patients were followed for another 73 days, during which the pump delivered an infusion of saline. The PET scan images showed that in the patients who received the active treatment - as opposed to placebo - levels of dopamine signaling were not only maintained, but even increased. http://www.medicalnewstoday.com/articles/289642.php |
||
Reply With Quote |
02-21-2015, 04:03 AM | #2 | |||
|
||||
Grand Magnate
|
Thanks for that link zanpar321.
It looks like a very encouraging study to me though 12 subjects is not a big number. The Journal of Clinical Investigation is a top-quality (impact factor ~14) journal so any manuscript which survives peer-review to get published there is worth careful attention. There is a free-access link to the paper here: http://www.jci.org/articles/view/79635 |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
1st patientPhase I clinical trial of the regenerative cell therapy NTCELL - pig cells | Parkinson's Disease | |||
Adult Stem Cell Research Reverses Effects of Parkinson's Disease in Human Trial | Parkinson's Disease | |||
Growth Factor promotes new neuron growth in mouse model and crosses BBB | Parkinson's Disease | |||
Growth factor stimulates rapid extension of key motor neurons in brain | ALS |